Zacks Research Has Weak Forecast for Bruker FY2024 Earnings

Bruker Co. (NASDAQ:BRKR - Free Report) - Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for shares of Bruker in a research report issued on Monday, December 23rd. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $2.39 for the year, down from their prior estimate of $2.40. The consensus estimate for Bruker's current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker's Q4 2024 earnings at $0.74 EPS, Q1 2025 earnings at $0.52 EPS, Q2 2025 earnings at $0.58 EPS, Q3 2025 earnings at $0.71 EPS, FY2025 earnings at $2.76 EPS, Q3 2026 earnings at $0.81 EPS and FY2026 earnings at $3.41 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The company had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. During the same quarter last year, the firm earned $0.74 EPS. The business's revenue was up 16.4% on a year-over-year basis.

BRKR has been the topic of a number of other reports. TD Cowen cut their target price on Bruker from $72.00 to $70.00 and set a "hold" rating on the stock in a research note on Wednesday, November 6th. Wolfe Research cut Bruker from an "outperform" rating to a "peer perform" rating in a research report on Monday, September 30th. Guggenheim began coverage on shares of Bruker in a research report on Thursday, December 19th. They set a "buy" rating and a $72.00 price target for the company. Bank of America boosted their target price on shares of Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research report on Friday, December 13th. Finally, UBS Group began coverage on shares of Bruker in a research report on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $74.45.

Bruker Trading Up 1.5 %

Shares of NASDAQ BRKR traded up $0.86 during midday trading on Wednesday, hitting $58.25. 462,999 shares of the company traded hands, compared to its average volume of 1,132,861. Bruker has a 12-month low of $48.07 and a 12-month high of $94.86. The firm has a market cap of $8.83 billion, a P/E ratio of 28.00, a P/E/G ratio of 4.00 and a beta of 1.18. The stock has a 50-day moving average price of $57.73 and a 200 day moving average price of $62.30. The company has a debt-to-equity ratio of 1.24, a quick ratio of 0.73 and a current ratio of 1.66.

Institutional Investors Weigh In On Bruker

Several hedge funds and other institutional investors have recently made changes to their positions in BRKR. True Wealth Design LLC boosted its holdings in Bruker by 4,636.4% during the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock valued at $36,000 after acquiring an additional 510 shares during the period. UMB Bank n.a. lifted its position in shares of Bruker by 115.3% during the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company's stock worth $46,000 after purchasing an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd purchased a new stake in shares of Bruker during the second quarter valued at $52,000. GAMMA Investing LLC grew its holdings in shares of Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company's stock worth $60,000 after purchasing an additional 388 shares during the last quarter. Finally, Values First Advisors Inc. bought a new position in shares of Bruker in the third quarter worth about $73,000. Hedge funds and other institutional investors own 79.52% of the company's stock.

Insiders Place Their Bets

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was purchased at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the acquisition, the chief executive officer now owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 28.30% of the company's stock.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.34%. The ex-dividend date was Monday, December 2nd. Bruker's dividend payout ratio is presently 9.62%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.